My Beauty Spot Acne Buster

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the soothing and reduction of redness and irritation associated with blemished skin. It also aids in the absorption of excess oil, promoting faster healing of affected areas.

There are no teratogenic or nonteratogenic effects mentioned in the available data.

Dosage and Administration

Healthcare professionals are advised to instruct patients to begin by cleansing and drying the face thoroughly, ensuring that any makeup is completely removed. Following this, patients should apply one healing dot, ensuring the sticky side is placed directly over the blemish.

The healing dot should be left in place for a minimum of 6 hours, although overnight application is recommended for optimal results. Patients may repeat this process as necessary, using a new healing dot for each application.

Contraindications

Use is contraindicated in children due to the risk of accidental ingestion. In the event of swallowing, immediate medical assistance or contact with a Poison Control center is advised.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to avoid concurrent use of this product with other topical acne medications, as this may increase the likelihood of skin irritation and dryness. In the event of irritation, it is recommended that patients limit their use to one topical acne medication at a time.

The ingredients in this formulation adhere to stringent quality standards; however, sensitivity reactions may occur in rare instances. Should any signs of sensitivity arise, patients must discontinue use immediately and seek appropriate medical advice.

In cases of accidental ingestion, it is imperative to seek medical assistance or contact a Poison Control center without delay.

Side Effects

Patients using this product should be aware that it is intended for external use only. The use of this product in conjunction with other topical acne medications may increase the likelihood of skin irritation and dryness. In the event that irritation occurs, it is recommended that patients discontinue the use of all topical acne medications and limit their regimen to one product at a time.

While the ingredients in this formulation meet high-quality standards, there are infrequent reports of sensitivity reactions. Should any sensitivity occur, patients are advised to discontinue use immediately to prevent further complications.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of My Beauty Spot Acne Buster (salicylic acid 0.5%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information available regarding the use of this drug during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment and the need to inform their healthcare provider if they become pregnant or plan to become pregnant while using this medication.

Lactation

There is no specific information available regarding the use of MY BEAUTY SPOT ACNE BUSTER (salicylic acid 0.5% patch) in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the lack of data when advising lactating mothers on the use of this product.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of specific guidance necessitates careful evaluation of the patient's overall health status and liver function.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous assessment and supportive measures should be prioritized until the patient stabilizes or further treatment is determined.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is vital for ongoing management and potential reporting requirements.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children. It is crucial to inform patients that if the medication is swallowed, they should seek medical help or contact a Poison Control center immediately. This precaution is essential to ensure the safety and well-being of children who may inadvertently access the medication.

Storage and Handling

The product is supplied in a configuration that ensures optimal handling and storage. It should be stored in a cool, dry place to maintain its integrity and effectiveness. It is essential to keep the product out of reach of children to prevent accidental ingestion. Once opened, the product must be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically and is intended for external use only. Clinicians should advise patients that the likelihood of skin irritation and dryness increases when using this product concurrently with other topical acne medications. If irritation occurs, patients should limit their use to one topical acne treatment at a time.

The formulation adheres to high-quality standards, though sensitivity may occur in rare cases; patients experiencing such reactions should discontinue use immediately. It is crucial to keep the product out of reach of children, and in the event of ingestion, medical assistance or contact with a Poison Control center is recommended.

Drug Information (PDF)

This file contains official product information for My Beauty Spot Acne Buster, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)